[Management of graft failure and erythroblastopenia in patients undergoing allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Fiche publication
Date publication
novembre 2016
Journal
Bulletin du cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr POCHON Cécile
Tous les auteurs :
Cornillon J, Sicre de Fontbrune F, Chantepie S, Coiteux V, Gauthier J, Masouridi-Levrat S, Pochon C, Terriou L, Yakoub-Agha I, Dalle JH
Lien Pubmed
Résumé
Success of allogeneic hematopoietic stem cells transplantation requires both the underlying disease eradication and satisfying reconstitution of hematopoiesis from donor cells. However, reconstitution delays, secondary development or persistence of cytopenia are regularly observed and are potential causes of failure after allogeneic transplantation. These graft dysfunctions should be distinguished from non-engraftment/engraftment failure. Although these situations are relatively common, there is no consensus in the literature for their management. During the workshop of the SFGM-TC, the working group proposed recommendations from an analysis of the literature.
Mots clés
Allogreffe de cellules souches hématopoïétiques, Bone marrow transplantation, Dysfonction du greffon, Erythroblastopenia, Graft dysfunction, Érythroblastopénie
Référence
Bull Cancer. 2016 Nov;103(11S):S248-S254